相关实验视频
Updated: Feb 11, 2026

20:38
Isolation and Transplantation of Hematopoietic Stem Cells HSCs
Published on: February 25, 2007
24.2K
用生物等价的通用莱特莫维尔进行二次预防在平同样性造血干细胞移植中:一个案例报告
Abhijit Baheti1, Suyash Bharat2
1Hematology, Deenanath Mangeshkar Hospital, Pune, IND.
Cureus
|February 10, 2026
概括
细胞巨乳病毒 (CMV) 再激活是干细胞移植后的一个风险. 这一案例表明,在初始预防后,口服瓦尔根西克洛维尔对CMV再激活的门诊治疗成功,突出显示了持续的抗病毒策略.
科学领域:
- 血液学 血液学 血液学
- 传染性疾病 传染性疾病
- 移植免疫学 移植免疫学
背景情况:
- 细胞巨乳病毒 (CMV) 反激活是所有原性造血干细胞移植 (HSCT) 后的一个主要并发症.
- 接受HSCT的高风险患者,特别是移植失败的患者,面临着对CMV感染的敏感性增加.
- 有效的CMV预防和管理对于改善移植结果至关重要.
研究的目的:
- 在患有复发性急性髓性白血病的患者中报告一个CMV再激活的病例,该病例是随着移植失败而发生的后哈普洛同一性HSCT.
- 为了说明短暂的CMV重新激活的成功门诊治疗.
- 强调持续的CMV预防和可获得的抗病毒疗法的重要性.
主要方法:
- 一名患有复发性急性髓性白血病的患者接受了单独的HSCT.
- 为了抑制CMV,进行了莱特莫维尔预防.
- 在停止预防治疗后发生了CMV的重新激活,并用口服瓦尔根西克洛维尔治疗.
- 监测临床过程和治疗反应.
主要成果:
- 莱特莫维尔预防最初成功抑制了CMV.
- 在停止莱特莫维尔预防后在HSCT后的+60天发生过渡性CMV重新激活.
- 门诊治疗用口服瓦尔根西克洛维尔有效地管理了CMV的重新激活.
- 患者成功实现了移植和临床康复.
结论:
- 在某些高风险的HSCT环境中,可能需要持续的CMV预防.
- 可获得的口服抗病毒药物,如瓦尔甘西克洛维尔,对于在门诊环境中管理CMV复激活是有效的.
- 优化抗病毒策略是改善CMV风险的HSCT接受者的结果的关键.
相关概念视频
Multipotency of Hematopoietic Stem Cells
3.9K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.9K
Regulation of Hematopoietic Stem Cells
4.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.1K
Bioequivalence: Overview
2.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.0K
Induced Pluripotent Stem Cells
28.1K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.1K
Primary and Secondary Growth in Roots and Shoots
60.7K
Vascular plants, which account for over 90% of the Earth’s vegetation, all undergo primary growth—which lengthens roots and shoots. Many land plants, notably woody plants, also undergo secondary growth—which thickens roots and shoots.
60.7K
Secondary Active Transport
138.1K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
138.1K

